Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’

Exelixis' investigational drug zanzalintinib, combined with Roche's Tecentriq, demonstrated a significant improvement in overall survival against Bayer's Stivarga in a pivotal Phase III trial for metastatic colorectal cancer, marking its first clinical success. This positive readout positions zanzalintinib as a key successor to Exelixis' top-selling drug cabozantinib, which loses patent exclusivity in 2030, thereby potentially extending the company's revenue stream and mitigating future sales erosion. The news propelled Exelixis shares up approximately 10%, with analysts projecting peak U.S. sales of $875 million for this indication and anticipating positive read-through for other zanzalintinib programs.

Analysis

Exelixis has announced a significant clinical victory with its third-generation tyrosine kinase inhibitor, zanzalintinib. The positive topline results from the Phase III STELLAR-303 trial, where zanzalintinib in combination with Roche's Tecentriq demonstrated a significant overall survival benefit versus Bayer’s Stivarga in metastatic colorectal cancer, marks a pivotal de-risking event for the drug's development program. This success is strategically crucial as it positions zanzalintinib as a viable successor to cabozantinib, the company's blockbuster franchise that generated $1.81 billion in U.S. sales last year and faces patent expiration in 2030. The market has reacted favorably, with shares rising approximately 10%, reflecting investor confidence in zanzalintinib's potential to secure future revenue streams. Analyst projections of $875 million in risk-adjusted U.S. peak sales for this indication alone underscore the commercial opportunity, with further upside potential from positive read-throughs to ongoing trials in renal cell carcinoma and head and neck cancer, which have catalysts expected in the second half of the year.

Key Decisions for Investors

• The positive Phase III data materially de-risks Exelixis's pipeline and provides a credible solution to the looming 2030 patent cliff for cabozantinib, strengthening the long-term fundamental value of the company.
• Investors should monitor key upcoming catalysts in the second half of the year, including the Phase III readout for zanzalintinib in renal cell carcinoma and a portfolio decision in head and neck cancer, which could drive further value accretion.
• While the topline success is a significant positive, a full assessment of zanzalintinib's competitive profile will require the release of specific efficacy and safety data, which should be scrutinized upon presentation at a future medical meeting.